CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
High ImpactOriginal article

Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal 

ABO2203Positive
AI Analysis

Summary

Novartis has agreed to acquire Abogen for $7.8 billion, gaining access to ABO2203, an mRNA-encoded T-cell engager designed to produce a protein in vivo for autoimmune conditions.

Importance:8/10
Sentiment:
0.70
acquisitionBiTEmRNAautoimmuneT-cell engagerin vivo
Related Companies

Read the original article

Published by Pharmaceutical Technology on October 2, 2026 10:24 AM

Read Original